Newsroom

Hangzhou, China, March 12, 2026 - Hangzhou Eli Radiopharma Co., Ltd. (“Eli Radiopharma”, or “the Company”), an innovative radiopharmaceutical company focused on integrated diagnostics and therapeutics for oncology and neurological diseases, today announced the completion of a new financing round of nearly RMB 100 million, with participation from Longfeng Venture, Echelon Capital, Hongsheng Capital, and Bioclub Fund.

Eli Radiopharma and HTA Co., Ltd. (HTA) have entered into a strategic collaboration to jointly advance innovation and establish a new ecosystem within the radiopharmaceutical industry.

Hangzhou, China - September 25, 2025 - Hangzhou Eli Radiopharma Co., Ltd. (“Eli Radiopharma”, “the Company”), an innovative radiopharmaceutical company dedicated to the integrated diagnosis and therapeutics of cancer and neurological diseases, today announced the completion of an extended angel financing round of over RMB 100 million.

Hangzhou, China - December 24, 2024 - Hangzhou Eli Radiopharma Co., Ltd. (“Eli Radiopharma”, the “Company”), a radiopharmaceutical company dedicated to innovative targeted radionuclide therapy with theranostics, today announced that it has raised RMB 100 million in an angel funding round to develop a cutting-edge radiopharmaceutical innovation platform, increase its research and development capabilities, accelerate Company’s clinical programs, and expand the team.